One other note: The velocity increase by which MimiVax surged enrollment between May 2023 and February 2024 was more indicative of big pharma speed. So was their interim analysis speed in Jan/Feb 2025. Hmm.
One other note: Survaxm Protocol: end of February 2024 last randomization patient followed for 548 days. Ended up same as Survaxm primary endpoint expected (in about 180 days (aka August 18, 2024) + another 365 days to report (aka August 18, 2025).
NWBO: DCVax-l beginning of March add 365 clock off allowable plus 210 clock on available = 575 days. (Curiosity, if you averaged the range of 150 and 210, it would be 545 days — September 3, 2025).
So because they probably could not tell if it was going 150 or 210 they used the 180 days as an average,
So, bear in mind, that theoretical DCVax-l MAA 545 days goes to September 3 2025 Just two weeks after Survaxm reporting date (which also could have some flex if it had been needed)
Likewise the final randomization in Survaxm February 23, 2024 made DCVax-L’s start date, validation date zero day clock start, just two weeks apart.
It seems pretty obvious this hypothesis comes across as NWBO wanting Survaxm results approximately right before DCVax-l maa decision timeline reaches its max length under the guidelines.
Market Data 
Markets 
AI
